Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 787809, 7 pages
http://dx.doi.org/10.1155/2015/787809
Research Article

Extramedullary Manifestation in Multiple Myeloma Bears High Incidence of Poor Cytogenetic Aberration and Novel Agents Resistance

Department of Hematology, Jiangsu Province Hospital, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Jiangsu, Nanjing 210029, China

Received 14 August 2014; Revised 24 September 2014; Accepted 25 September 2014

Academic Editor: Fenghuang Zhan

Copyright © 2015 Xiaoyan Qu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Bladé, C. F. de Larrea, and L. Rosiñol, “Extramedullary involvement in multiple myeloma,” Haematologica, vol. 97, no. 11, pp. 1618–1619, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Varettoni, A. Corso, G. Pica, S. Mangiacavalli, C. Pascutto, and M. Lazzarino, “Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients,” Annals of Oncology, vol. 21, no. 2, pp. 325–330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Wu, F. E. Davies, K. Boyd et al., “The impact of extramedullary disease at presentation on the outcome of myeloma,” Leukemia and Lymphoma, vol. 50, no. 2, pp. 230–235, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Bladé, J. A. Lust, and R. A. Kyle, “Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases,” Journal of Clinical Oncology, vol. 12, no. 11, pp. 2398–2404, 1994. View at Google Scholar · View at Scopus
  5. J. Bladé, R. A. Kyle, and P. R. Greipp, “Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years,” British Journal of Haematology, vol. 93, no. 2, pp. 345–351, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Z. Usmani, C. Heuck, A. Mitchell et al., “Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents,” Haematologica, vol. 97, no. 11, pp. 1761–1767, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Rasche, C. Bernard, M. S. Topp et al., “Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases,” Annals of Hematology, vol. 91, no. 7, pp. 1031–1037, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. K. D. Short, S. V. Rajkumar, D. Larson et al., “Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma,” Leukemia, vol. 25, no. 6, pp. 906–908, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Moriuchi, K. Ohmachi, M. Kojima et al., “Three cases of bortezomib-resistant multiple myeloma with extramedullary masses,” Tokai Journal of Experimental and Clinical Medicine, vol. 35, no. 1, pp. 17–20, 2010. View at Google Scholar · View at Scopus
  10. L. Rosiñol, M. T. Cibeira, J. Bladé et al., “Extramedullary multiple myeloma escapes the effect of thalidomide,” Haematologica, vol. 89, no. 7, pp. 832–836, 2004. View at Google Scholar · View at Scopus
  11. J. Bladé, M. Perales, L. Rosiñol et al., “Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas,” British Journal of Haematology, vol. 113, no. 2, pp. 422–424, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. J. R. Mikhael, D. Dingli, V. Roy et al., “Management of newly diagnosed symptomatic multiple myeloma: Updated mayo stratification of myeloma and risk-adapted therapy (msmart) consensus guidelines 2013,” Mayo Clinic Proceedings, vol. 88, no. 4, pp. 360–376, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. P. R. Greipp, J. S. Miguel, B. G. M. Dune et al., “International staging system for multiple myeloma,” Journal of Clinical Oncology, vol. 23, no. 15, pp. 3412–3420, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Fonseca, E. A. Blood, M. M. Oken et al., “Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients,” Blood, vol. 99, no. 10, pp. 3735–3741, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Avet-Loiseau, X. Leleu, M. Roussel et al., “Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p),” Journal of Clinical Oncology, vol. 28, no. 30, pp. 4630–4634, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. G. An, Y. Xu, L. Shi et al., “Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value,” Haematologica, vol. 99, no. 2, pp. 353–359, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Billecke, E. M. M. Penas, A. M. May et al., “Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma,” Anticancer Research, vol. 32, no. 5, pp. 2031–2034, 2012. View at Google Scholar · View at Scopus
  18. H. Chang, S. Sloan, D. Li, and A. K. Stewart, “Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions,” British Journal of Haematology, vol. 127, no. 3, pp. 280–284, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Billecke, E. M. Murga Penas, A. M. May et al., “Cytogenetics of extramedullary manifestations in multiple myeloma,” British Journal of Haematology, vol. 161, no. 1, pp. 87–94, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. B. G. M. Durie and S. E. Salmon, “A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival,” Cancer, vol. 36, no. 3, pp. 842–854, 1975. View at Publisher · View at Google Scholar · View at Scopus
  21. B. G. M. Durie, J.-L. Harousseau, J. S. Miguel et al., “International uniform response criteria for multiple myeloma,” Leukemia, vol. 20, no. 9, pp. 1467–1473, 2006. View at Google Scholar · View at Scopus
  22. L. Chen, C. Li, R. Zhang et al., “MiR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma,” Cancer Letters, vol. 309, no. 1, pp. 62–70, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. A. B.-T. Fassas, S. Ward, F. Muwalla et al., “Myeloma of the central nervous system: Strong association with unfavorable chromosomal abnormalities and other high-risk disease features,” Leukemia and Lymphoma, vol. 45, no. 2, pp. 291–300, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Rosiñol, M. T. Cibeira, C. Uriburu et al., “Bortezomib: an effective agent in extramedullary disease in multiple myeloma,” European Journal of Haematology, vol. 76, no. 5, pp. 405–408, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Paubelle, P. Coppo, L. Garderet et al., “Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: Possible enhancement of graft-vs-tumor effect,” Leukemia, vol. 19, no. 9, pp. 1702–1704, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Patriarca, S. Prosdocimo, V. Tomadini, A. Vasciaveo, B. Bruno, and R. Fanin, “Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloabiatlve allogeneic transplantation,” Haematologica, vol. 90, no. 2, pp. 278–279, 2005. View at Google Scholar · View at Scopus
  27. J. F. San Miguel, R. Schlag, N. K. Khuageva et al., “Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma,” The New England Journal of Medicine, vol. 359, no. 9, pp. 906–917, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Pineda-Roman, M. Zangari, J. Haessler et al., “Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2,” British Journal of Haematology, vol. 140, no. 6, pp. 625–634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. P. L. Bergsagel and W. M. Kuehl, “Molecular pathogenesis and a consequent classification of multiple myeloma,” Journal of Clinical Oncology, vol. 23, no. 26, pp. 6333–6338, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Fonseca, P. L. Bergsagel, J. Drach et al., “International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review,” Leukemia, vol. 23, no. 12, pp. 2210–2221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Biran, J. Malhotra, E. Bagiella, H. J. Cho, S. Jagannath, and A. Chari, “Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens,” American Journal of Hematology, vol. 89, no. 6, pp. 616–620, 2014. View at Publisher · View at Google Scholar · View at Scopus